Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase-II Study of Olaparib as Maintenance Therapy After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma

NCT03470805 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Cáncer de Ovario as lead sponsor.

NCT NCT03470805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03470805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase-II Study of Olaparib as Maintenance Therapy After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma
Lead sponsor
Grupo Español de Investigación en Cáncer de Ovario
Phase
Phase 2
Overall status
Completed
Start date
June 21, 2018
Completion date
July 27, 2022
Enrollment
9 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer